The PRECISEU project has published a call to support innovative interregional projects in personalised medicine under the Regional Innovation Valleys framework. The call will empower SMEs, startups and innovation actors to develop and scale solutions in ATMPs and health data, strengthening regional ecosystems and accelerating the uptake of high-impact, patient-centred innovations across Europe.
PRECISEU is a Horizon Europe project focused on strengthening interregional innovation ecosystems in
personalised medicine. The PRECISEU Open Call is designed to fund Innovation Action-like projects that accelerate the development, validation or implementation readiness of solutions in personalised medicine. The call particularly seeks proposals that improve accessibility and affordability, reinforce regional innovation
capacity, strengthen Europe’s position in advanced therapeutics and health data, and promote knowledge
transfer across ecosystems.
The call is open to legal entities from EU Member States and Horizon Europe Associated Countries. Eligible
organisation types include companies, SMEs, research institutes, universities, technology centres, hospitals, public administrations, associations, NGOs and other relevant bodies. Only beneficiaries established in regions covered by a participating Funding Agency are eligible to receive PRECISEU financial support.
The call targets deep-tech innovation in personalised medicine and supports activities centred on
experimental development, typically at Technology Readiness Levels 6 to 8. The technical scope is organised around two topics:
- Advanced therapeutics and
- Health data for personalised medicine
Projects may address one topic or, where properly justified, both.
Eligible activities include, among others, scale-up work where genuine scientific or technical uncertainty remains, optimisation and validation of analytical methods, development of improved in vivo, in silico or in vitro models, generation of evidence to resolve technical uncertainty, end-user collaborative projects that support iterative experimental development, and regulatory-readiness activities linked to the innovation pathway. Activities related to routine market uptake, roll-out, commercial distribution or other purely commercial steps are not eligible.
Proposals must be submitted until 14 June 2026.